We hypothesize that Fas/Fas ligand-dependent cytotoxic T lymphocyte (CTL) effector mechanisms are critically important in killing of virally infected hepatocytes. This contrasts with CTL responses to allogeneic or virally infected target cells of non- hepatic origin, where perforin-dependent mechanisms play a more prominent role. The hypothesis is based on preliminary studies indicating that defects in Fas/Fas ligand-dependent immune effector mechanisms greatly prolong in vivo expression of adenovirus encoded genes in the liver. Moreover, CTL killing of hepatocyte targets appears to be largely Fas ligand-dependent and is not dramatically impaired by perforin deficiency. In the proposed studies, we will test this hypothesis by examining mechanisms involved in CTL-mediated killing of hepatocyte targets and silencing of virally encoded genes expressed in hepatocytes. We will isolate intrahepatic CTL from adenovirus infected mice and directly examine the cytolytic effector mechanisms utilized in killing adenovirus-infected hepatocytes. The adhesion and other co-stimulatory molecules that are expressed by adenovirus-specific CTL and play a role in interactions with adenovirus-infected hepatocytes will be identified. We will determine whether different CTL effector mechanisms silence adenovirally transduced foreign genes encoding cytosolic, cell surface or secreted proteins. The hypothesis, that selective modulation of Fas-dependent effector mechanisms by adenovirus encoded immunomodulatory proteins will significantly alter the duration of hepatic expression of other virally encoded genes, will be tested. These studies will provide insights into CTL effector mechanisms involved in clearance of viral infections from the liver and have the potential to direct strategies that enhance and prolong expression of liver-directed gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK053933-04
Application #
6517459
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Doo, Edward
Project Start
1999-07-01
Project End
2004-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
4
Fiscal Year
2002
Total Cost
$289,662
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Getachew, Yonas; James, Laura; Lee, William M et al. (2010) Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. Biochem Pharmacol 79:1363-71
Getachew, Yonas; Stout-Delgado, Heather; Miller, Bonnie C et al. (2008) Granzyme C supports efficient CTL-mediated killing late in primary alloimmune responses. J Immunol 181:7810-7
Stout-Delgado, Heather W; Getachew, Yonas; Miller, Bonnie C et al. (2007) Intrahepatic lymphocyte expression of dipeptidyl peptidase I-processed granzyme B and perforin induces hepatocyte expression of serine proteinase inhibitor 6 (Serpinb9/SPI-6). J Immunol 179:6561-7
Stout-Delgado, Heather W; Getachew, Yonas; Rogers, Thomas E et al. (2007) The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity. Hepatology 46:1530-40
Abougergi, Marwan S; Gidner, Sarah J; Spady, David K et al. (2005) Fas and TNFR1, but not cytolytic granule-dependent mechanisms, mediate clearance of murine liver adenoviral infection. Hepatology 41:97-105
Barrie, Mahmoud B; Stout, Heather W; Abougergi, Marwan S et al. (2004) Antiviral cytokines induce hepatic expression of the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor 6. J Immunol 172:6453-9
Kafrouni, Michel I; Brown, Geri R; Thiele, Dwain L (2003) The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J Leukoc Biol 74:564-71
Kafrouni, M I; Brown, G R; Thiele, D L (2001) Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J Immunol 167:1566-74